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Autoimmune pancreatitis (AIP) is a distinct type of chronic pancreatitis with unique clinical, pathological, serological, and 
imaging features. AIP usually presents with obstructive jaundice. Imaging studies often reveal enlargement of the pancreas 
with a pancreatic mass and strictures of the main pancreatic duct. Two subtypes of AIP have recently been identified. Type I 
AIP is more prevalent in elderly Asian males and is characterized by lymphoplasmacytic sclerosing pancreatitis, obliterative 
phlebitis, and infiltration of large numbers of IgG4-positive plasma cells. Type II AIP is more prevalent in Caucasians and is 
characterized by granulocyte epithelial lesions. Most patients with type I AIP have a significantly elevated serum IgG4 con-
centration, which is an important feature for diagnosis and for differentiating between AIP and other conditions such as pan-
creatic cancer. Extrapancreatic complications are common, such as sclerosing cholangitis, sclerosing sialadenitis, retroperito-
neal fibrosis in type I AIP, and ulcerative colitis in type II AIP. A rapid response to glucocorticoids treatment is suggestive of 
AIP, but the relapse rate is high, warranting the use of immunosuppressant treatment. B-cell depletion with rituximab may be a 
promising therapy. The prognosis of AIP is generally benign if treated promptly, and spontaneous remission occurs in a pro-
portion of patients. 
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Autoimmune pancreatitis (AIP) is an uncommon form of 
chronic pancreatitis with a presumed autoimmune etiology 
and unique clinical, pathological, serological, and imaging 
features. Increasing numbers of cases have been reported 
over the past several decades. Chronic pancreatitis with 
sclerosis was first described as an autoimmune condition by 
Sarles et al. in 1961 [1], but it was not until 1995 that Yo-
shida et al. [2] proposed the term “autoimmune pancreatitis”. 
In 2001, elevated serum immunoglobulin (Ig) G4 concen-
trations were detected in a large proportion of patients with 
AIP [3]. Two years later, Kamisawa et al. [4] reported ex-
tensive IgG4-positive plasma cell infiltration and fibrosis in 
the pancreas and other organs of patients with AIP. From 
then on, AIP has been considered to be part of a systemic 
sclerosing disorder. Similar cases with pathological features 
of multifocal fibrosclerosis were identified as early as the 
1960s [5], and are now retrospectively described as IgG4-    
related sclerosing disease. 
The nomenclature for AIP has evolved over the past 
decade, and now includes the terms lymphoplasmacytic 
sclerosing pancreatitis (LPSP), granulocyte epithelial lesion 
(GEL)-associated pancreatitis, and idiopathic duct-centric 
chronic pancreatitis. This changing nomenclature reflects 
our increasing understanding of this previously underesti-
mated disease. 
1  Subtypes of AIP 
The cases of AIP reported in Asian patients (mainly Japa-
nese patients) differ from those reported in Caucasian pa-
tients in terms of clinical manifestations and pathological 
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characteristics [6,7]. In 2011, AIP was classified into two 
subtypes by an international consensus meeting for AIP 
coordinated by the Autoimmune Pancreatitis International 
Study Group [8]. Type I AIP usually affects elderly Asian 
males and has histopathological characteristics of LPSP; 
this is currently considered to be a pancreatic manifestation 
of IgG4-related disease. Type II AIP, previously called 
GEL-associated AIP, more commonly affects young Cauca-
sian patients, with no sex predominance. Type II AIP fea-
tures neutrophil infiltration in and around the pancreatic 
duct, and is associated with inflammatory bowel disease [9]. 
The characteristics of these two subtypes are summarized in 
Table 1. 
2  Epidemiology 
The worldwide prevalence of AIP remains unknown. Most 
studies are of type I AIP in the Japanese population. Ac-
cording to a nationwide study, the estimated prevalence of 
AIP in Japan is 0.82/100000 [10], but this prevalence may 
be underestimated because of a lack of awareness of the 
disease and lack of availability of IgG4 testing. AIP ac-
counts for 2%–6% of chronic pancreatitis [10,11]. In pa-
tients who underwent pancreatic resection for suspected 
malignancy, 2.5%–8% were ultimately diagnosed with AIP 
without malignancy [10,12]. Data from the Mayo Clinic 
revealed that 11% of 245 patients who underwent pancreatic 
resection for the treatment of chronic pancreatitis were ul-
timately diagnosed with AIP [13]. In Italy, type II AIP was 
diagnosed in 40% of highly selected surgical specimens 
from patients with idiopathic chronic pancreatitis without 
pseudocysts, calculi, irregular duct dilatation, pancreas di-
visum, and duodenal wall cysts [14].  
Type I AIP is more prevalent in patients aged 60–70 
years, whereas type II AIP tends to affect the younger pop-
ulation. As shown in Table 1, type I AIP has a male: female 
ratio of approximately 2.85:1 [10], whereas there is no sex 
predominance in type II AIP. 
3  Pathology 
The characteristic pathological findings are more important 
for the diagnosis of AIP than an elevated serum IgG4 con-
centration or IgG4-positive plasma cell infiltration. The 
major histopathological findings in type I AIP include dense 
periductal lymphoplasmacytic infiltration, storiform fibrosis, 
and obliterative phlebitis, which are described as LPSP. 
Immunohistochemical examination showing infiltration of 
large numbers of IgG4-positive cells (>10 per high-power 
field) is also helpful for diagnosing type I AIP. At least 
three of these four pathological features are required for a 
diagnosis of type I AIP. Mild to moderate eosinophil infil-
tration may also be present. The inflammatory lesion fre-
quently forms a tumefactive mass that may lead to the de-
struction of the pancreas [9]. The pancreatic duct is com-
pressed by surrounding fibrosis and lymphoplasmacytic 
infiltration. Unlike in type II AIP, neutrophil infiltration and 
granuloma formation are rare in type I AIP, and the ductal 
epithelium is usually intact. The retroperitoneal peripancre-
atic soft tissue frequently has extensive inflammatory cell 
infiltration. Type II AIP is characterized by neutrophil infil-
tration in and around the pancreatic duct leading to duct 
destruction, which is described as GEL. Although lympho-
plasmacytic infiltration and storiform fibrosis may be ob-
served in type II AIP, they are less common than in type I 
AIP [14]. Intrapancreatic pseudocysts, intraductal protein 
plugs, and pancreatic stones are seldom observed in either 
subtype of AIP, which differentiates AIP from other forms  
Table 1  Subtypes of autoimmune pancreatitis 
 Type I Type II 
Demographics   
 Race Asian Caucasian 
 Male/female ratio 2.85:1 ~1:1 
Clinical manifestation   
 Pancreatic Painless obstructive jaundice is common 
Obstructive jaundice with acute pancreatitis-like ab-
dominal pain 
 Extra-pancreatic 








Swollen pancreas, mass formation, multiple pancreatic 
duct strictures 
Swollen pancreas, mass formation, multiple pancreatic 
duct strictures 
Pathology 
IgG4-positive plasma cells and T-lymphocytes infil-
tration, storiform fibrosis, obliterative phlebitis, eo-
sinophil infiltration 
Neutrophilic infiltration in/around the pancreatic duct, 
duct destruction, obliterative phlebitis rare 
Treatment   
 Steroids response Prompt response Prompt response 
 Relapse rate High Low 
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of chronic pancreatitis. 
In type I AIP, similar pathological features to those seen 
in the pancreas are also seen in other affected organs such 
as the biliary ducts, salivary glands, lacrimal glands, and 
thyroid, suggesting that type I AIP is the pancreatic mani-
festation of a systemic IgG4-related sclerosing disease. 
Pathological differences may occur between organs. For 
example, obliterative phlebitis is common in the pancreas 
and submandibular glands of patients with type I AIP, but is 
much less common in the pancreas of patients with type II 
AIP and in the lacrimal glands. 
Although the presence of IgG4-positive plasma cells is 
important for the diagnosis of AIP, these cells are also 
found in a wide variety of other inflammatory diseases. De-
tection of IgG4-positive plasma cell infiltration is therefore 
not pathognomonic for AIP. However, a ratio of 
IgG4-positive to total IgG-positive plasma cells of >50% is 
very suggestive of AIP [15]. 
4  Clinical manifestations 
Most patients with AIP do not have constitutional inflam-
matory manifestations. Fever and an elevated serum 
C-reactive protein level are uncommon. Most patients have 
an insidious onset, and AIP is usually identified incidentally 
on radiological examination or unexpectedly in pathological 
specimens. The clinical manifestations of AIP may be both 
pancreatic and extrapancreatic. 
The most typical pancreatic finding in both subtypes of 
AIP is obstructive jaundice with sclerosing cholangitis. Oc-
casionally, AIP presents with mild abdominal pain and ele-
vated serum amylase or lipase levels, mimicking acute pan-
creatitis. AIP may also present with steatorrhea and pancre-
atic calcification that is suggestive of chronic pancreatitis. 
In the chronic phase of AIP, patients may present with pan-
creatic atrophy leading to steatorrhea. In some cases, biliary 
system involvement with obstructive jaundice is easily mis-
diagnosed as cholangiocarcinoma. In 60%–70% of patients, 
AIP is complicated by impaired glucose tolerance or diabe-
tes mellitus. One third of patients have diabetes mellitus 
prior to the onset of AIP, and half of patients develop dia-
betes simultaneously with AIP [16,17]. Glucocorticoid 
treatment is helpful for glycemic control in a proportion of 
these patients, suggesting that the diabetes is associated 
with inflammation of the pancreas. 
Awareness of extrapancreatic involvement is important, 
because it may be helpful in the diagnosis of AIP when the 
pancreatic manifestations are equivocal, and can provide 
alternative or additional biopsy sites. Extrapancreatic in-
volvement can also be used to monitor the response to 
treatment. Some patients with AIP have isolated pancreatic 
manifestations for many years before diagnosis, whereas 
others may present with subtle or obvious extrapancreatic 
manifestations together with pancreatic symptoms. Extra-
pancreatic involvement includes Mikulicz’s syndrome, retro-  
peritoneal fibrosis, Kuttner’s tumor, inflammatory pseudo-
tumor, Riedel’s thyroiditis, and tubulointerstitial nephritis 
[18,19]. These conditions have similar pathological features 
to those seen in type I AIP. Spontaneous recovery is re-
ported in some patients. 
5  Laboratory findings 
5.1  IgG4 detection 
Although most patients with type I AIP have elevated serum 
IgG4 concentrations, approximately 30% have normal se-
rum IgG4 concentrations, despite typical histopathological 
and immunohistochemical findings [20]. Recent studies 
reported that serum IgG4 concentration has a sensitivity of 
77% and specificity of 90% for diagnosing AIP, which is 
much lower than previously estimated [3,21,22]. In another 
study of type I AIP, elevated serum IgG4 concentrations 
were found in 80% of patients [23]. The diagnostic value of 
an elevated serum IgG4 concentration increases with a 
higher cut-off point; the cut-off point for diagnosis is cur-
rently set at twice of the upper limit of normal. However, an 
elevated serum IgG4 concentration is not a specific diag-
nostic marker for AIP [24], especially in patients with mild 
to moderate elevation. It is extremely important to avoid 
over-diagnosis of AIP because of over-reliance on mild to 
moderate elevation of serum IgG4 concentration and 
IgG4-positive plasma cell infiltration as diagnostic markers. 
It is important not to use serum IgG4 concentration as an 
isolated indicator of disease activity. The use of serial 
measurements of IgG4 concentration to monitor disease 
activity is controversial. Only 30% of patients with persis-
tently elevated IgG4 concentrations experience relapses, 
and up to 10% of patients with normal IgG4 concentrations 
at follow-up experience relapse [25]. Although the serum 
IgG4 concentration decreases after glucocorticoid treatment 
in the majority of patients, it seldom returns to the normal 
range [20,26]. Serum IgG4 concentration rebounds after 
discontinuation of glucocorticoids treatment in most pa-
tients, but fortunately only a small proportion of these pa-
tients experience relapse. A multicenter study in Japan 
showed that serum IgG4 concentration failed to normalize 
in 115 of 182 patients (63%) undergoing glucocorticoid 
treatment [25]. The study also found that the disease re-
mained in remission in most patients, despite the persistent 
elevation in serum IgG4 concentration. 
5.2  Autoantibodies 
It has been reported that most patients with AIP have anti-
bodies against the plasminogen-binding protein (PBP) of 
Helicobacter pylori [27]. The antibodies directed against the 
bacterial components are presumed to act as auto-antibodies 
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by means of molecular mimicry in genetically predisposed 
individuals. The study suggested that detection of anti-PBP 
antibodies together with an elevated serum IgG4 concentra-
tion might improve the diagnostic accuracy of AIP. Of the 
35 patients in the study, two tested negative for anti-PBP 
antibodies but had elevated IgG4 concentrations, and 16 had 
normal IgG4 concentrations (maybe type II AIP patients) 
but tested positive for anti-PBP antibodies. The reported 
sensitivity and specificity of anti-PBP antibodies for differ-
entiating between AIP and pancreatic cancer were 94% and 
95%, respectively. It is unclear whether anti-PBP antibodies 
are associated with the subtype of AIP. 
Other AIP-related antibodies have also been reported, such 
as anti-lactoferrin, anti-carbonic anhydrase-II/IV [28,29], 
anti-pancreatic secretory trypsin inhibitor [30], anti-amylase- 
alpha [31], and anti-heat-shock protein-10 antibodies [32]. 
However, data about these auto-antibodies are not available 
in Caucasian patients, most of whom have type II AIP. The 
clinical significance of these autoantibodies in AIP there-
fore remains unclear. 
6  Imaging studies 
Imaging is often necessary for the diagnosis of AIP, even 
though the imaging findings are generally nonspecific and 
cannot reliably differentiate between AIP and malignancy. 
6.1  Computerized tomography (CT) and magnetic 
resonance imaging (MRI) 
In patients with AIP, CT commonly shows a swollen, “sau-
sage-like” pancreas with poorly visualized borders and a 
capsule-like low-density rim [33]. The enlarged pancreas is 
well enhanced in the delayed phase (Figure 1). A peripan-
creatic halo indicates a fibroinflammatory process extending 
into the peripancreatic adipose tissues, and diffuse narrow-
ing of the pancreatic duct indicates non-occlusive peri-     
ductal inflammation [34]. 
 
 
Figure 1  A 56-year-old woman with type I autoimmune pancreatitis. 
Enhanced abdominal CT showed a diffusely enlarged pancreas (“sau-
sage-like”) with enhancement, and a capsule-like low-density rim (arrow). 
On MRI, T1-weighted images (T1WI) and T2WI often 
have less intense signal than the liver. Magnetic resonance 
cholangiopancreatography (MRCP) is a less invasive mo-
dality for imaging the pancreatic and bile ducts. The pres-
ence of diffuse narrowing and side branches without up-
stream dilation of the main pancreatic duct supports a diag-
nosis of AIP [35]. 
6.2  Endoscopic retrograde cholangiopancreatography 
(ERCP) and endoscopic ultrasonography (EUS) 
ERCP is helpful for diagnosing AIP. Images may show a 
long, narrow ductal stricture (>1/3 of the main pancreatic 
duct) with side branches extending from the stricture, or 
multiple non-continuous strictures [36]. 
EUS is also useful for diagnosing AIP. The pancreas may 
show diffuse hypoechoic swelling with hyperechoic spots. 
EUS-guided fine-needle aspiration can be used to rule out 
pancreatic cancer, but the tissue obtained is usually insuffi-
cient to make a diagnosis of AIP. A core biopsy of the pan-
creas is required to definitively show the typical features of 
AIP [37]. 
7  Diagnosis and differential diagnosis 
7.1  Diagnostic criteria 
As pathological diagnosis of AIP requires invasive proce-
dures, alternative diagnostic criteria have been developed, 
so that invasive procedures are required only in the most 
challenging cases. At least eight sets of diagnostic criteria 
have been proposed since 2002, including criteria by the 
Japan Pancreas Society (2002 and 2006) [38], Italy (2003 
and 2009), the United States (the Mayo Clinic HISORt crite-
ria (Histology, Imaging, Serology, Other Organ Involvement 
and Response to Therapy), 2006), Korea (2007), the Asian 
consensus criteria (2008), and the International Consensus 
Diagnostic Criteria (ICDC 2011) [8,39–41]. These criteria 
use a combination of clinical, serological, pathological, and 
imaging findings to diagnose AIP. The earlier sets of criteria 
mainly aimed to avoid missing cases of resectable pancreatic 
cancer, rather than confirm the diagnosis of AIP. The 
HISORt criteria have been the most widely adopted in the 
literature, and can be applied in daily clinical practice because 
of their simplicity and clarity. However, they only describe 
the features of type I AIP, and may miss cases of type II AIP. 
The ICDC 2011 criteria are also highly recommended, and 
incorporate the most up-to-date knowledge on both types of 
AIP. The ICDC 2011 criteria are comprehensive and detailed, 
and can be applied to clinical research, but may be too com-
plicated for regular use in high-volume clinics. 
7.2  Differential diagnosis 
AIP may be misdiagnosed as many other pancreatic diseas-
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es, including pancreatic cancer. Many patients with AIP 
have clinical and laboratory findings that are indistinguish-
able from pancreatic cancer, such as painless obstructive 
jaundice, elevated tumor markers, focal swelling or mass in 
the pancreas, stenosis of the biliary and pancreatic ducts, 
and encasement of peri-pancreatic arteries and portal veins. 
This often leads to unnecessary laparotomy or surgery be-
cause pancreatic cancer has a worse prognosis than AIP. 
Radiological images showing diffuse swelling of the 
pancreas with a long stricture of the main pancreatic duct 
support a diagnosis of AIP. Upstream ductal dilation is rela-
tively rare. On diffusion weighted MRI, AIP often shows 
multiple diffuse hyper-intense signals, while pancreatic 
cancer usually shows solitary signal. Apparent diffusion 
coefficient values are much higher in pancreatic cancer than 
in AIP [35]. A low-density mass that abruptly occludes the 
main pancreatic duct with distal atrophy is suggestive of 
pancreatic cancer. Other findings, such as intrahepatic met-
astatic lesions, are also helpful for diagnosing pancreatic 
cancer [29]. 
Involvement of extrapancreatic organs such as the lacri-
mal and salivary glands, retroperitoneum, lymph nodes, and 
kidneys is helpful for diagnosing AIP. Although 4%–7% of 
patients with pancreatic cancer have an elevated serum 
IgG4 concentration [22,42], a serum IgG4 concentration 
of >280 mg dL1 is highly suggestive of AIP but not pan-
creatic cancer [23]. A diffuse plasma cell infiltrate with >30 
IgG4-positive cells per high-power field and a ratio of IgG4 
to total IgG of >50%, together with the characteristic histo-
pathological findings, supports a diagnosis of AIP. Tissues 
from patients with AIP often show diffuse infiltration rather 
than focal aggregates of IgG4-positive plasma cells. 
Although most patients with AIP respond promptly to 
glucocorticoid treatment, a trial of glucocorticoid treatment 
to differentiate between AIP and pancreatic cancer should 
be delayed until screening for pancreatic cancer has been 
completed, including EUS-guided fine-needle aspiration. If 
the patient does not respond as well to glucocorticoid treat-
ment as expected, re-evaluation for pancreatic cancer should 
be undertaken. As a few patients with AIP develop pancre-
atic stones or malignancy during or after glucocorticoids 
therapy [43], close follow-up is warranted. 
Lymphoma may mimic the histopathological manifesta-
tions of IgG4-related disease, and must be ruled out by 
clonality study. An early clue to the diagnosis of B-cell 
lymphoma is a predominantly B-cell infiltration. In contrast, 
the lymphoid inflammatory infiltration in AIP consists 
mainly of T-cells. 
8  Treatment 
8.1  Glucocorticoids 
Patients with AIP who receive glucocorticoid treatment  
have significantly higher remission rates of all aspects of 
clinical, histopathological, and serological findings than 
those who do not. Glucocorticoid treatment has also been 
reported to reduce the time to remission and improve the 
exocrine function of the pancreas [44,45]. The response to 
glucocorticoid treatment can be useful for differentiating 
between AIP and other pancreatic diseases. This character-
istic has been incorporated into the Korean and Mayo Clinic 
diagnostic criteria for AIP, even though it has not been 
evaluated in a randomized trial, and most of our knowledge 
regarding treatment responses is derived from retrospective 
observational case studies with insufficient follow-up time. 
It is emphasized that when vital organs are affected, aggres-
sive glucocorticoid treatment is warranted, because un-
treated IgG4-related disease can lead to severe organ dys-
function and failure. However, not all manifestations of the 
disease require immediate intervention, and the implemen-
tation of treatment also depends on the significance, func-
tional status, and disease course of the organ affected. In 
some cases, the extent of disease does not warrant treatment. 
The suggested indications for glucocorticoid treatment in-
clude obstructive jaundice, abdominal pain, back pain, and 
symptomatic extrapancreatic lesions. 
The Mayo Clinic has proposed treatment for AIP with 
prednisone 40 mg d1 for 4 weeks, followed by tapering of 5 
mg/week. However, more than 50% of patients treated ac-
cording to this regimen relapsed in a median time of 3 
months (0–14 months) after discontinuing prednisone. 
Kamisawa et al. [25] conducted a retrospective multicenter 
study in Japan to evaluate the efficacy of glucocorticoid 
treatment for AIP, which included 17 referral centers and 
563 patients. Patients were treated with prednisolone at a 
dose of 0.6 mg kg1 d1 for 2–4 weeks followed by a taper-
ing dose over 3–6 months and then continuing with 2.5–5.0 
mg d1 for up to 3 years. The remission rate was signifi-
cantly higher in patients who received glucocorticoid treat-
ment than those who did not (98% vs. 74%, P<0.001). Only 
32% of patients treated with longer-term therapy experi-
enced disease relapse within 6 months. Both subtypes of 
AIP respond promptly to glucocorticoid treatment, but the 
relapse rate was higher in patients with type I than with type 
II AIP, suggesting that different glucocorticoid maintenance 
regimens may be appropriate for different subtypes and that 
addition of immunosuppressant treatment may be warranted 
in patients with type I AIP.  
The response to glucocorticoid treatment should be com-
prehensively evaluated, including improvements in symp-
toms (jaundice and abdominal pain, but not fatigue), bio-
chemistry (liver function tests), serology (serum IgG4 con-
centration), and imaging findings (bile duct strictures and 
abnormal appearance of the pancreas on CT). Symptoms are 
usually relieved within 2 weeks after the initiation of glu-
cocorticoid treatments, but the other manifestations do not 
always respond as rapidly. For AIP complicated by cholan-
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gitis in patients with a biliary stent, glucocorticoid treatment 
may expedite the removal of the stent. Patients with extra-
pancreatic involvement generally respond well to glucocor-
ticoid treatment, except when there is extensive fibrosis 
such as in cases of Riedel’s thyroiditis or end-stage retro-
peritoneal fibrosis.  
There is concern regarding the long-term use of gluco-
corticoid treatment in patients with AIP, who are often el-
derly and have an increased risk of developing osteoporosis, 
glucose intolerance, and gastrointestinal complications. 
Long-term glucocorticoid treatment may exacerbate pre-       
existing glucose intolerance caused by the underlying AIP, 
even though treatment may initially improve glucose intol-
erance. Only 40% of patients who have spontaneous remis-
sion without glucocorticoid treatment subsequently relapse. 
Long-term glucocorticoid treatment may therefore only be 
necessary in patients who tend to relapse and may be used 
at low dose. 
8.2  Immunosuppressive agents 
Immunosuppressive agents have been used for the treatment 
of refractory or recurrent AIP. However, data about their 
efficacy and treatment course are limited. Azathioprine, 
mycophenolate mofetil, 6-mercaptopurine, cyclophospha-
mide, and methotrexate are the most commonly used glu-
cocorticoid-sparing and remission-maintenance drugs, but 
they have not yet been evaluated in clinical trials. The Mayo 
Clinic has proposed the use of immunosuppressive agents 
only in patients who have failed prednisone tapering at least 
once. The first choice of drug is either azathioprine (2.0–2.5 
mg kg1 d1) or mycophenolate mofetil (750 mg twice daily) 
[46]. 
8.3  Biological agents 
For patients with recurrent or refractory disease in spite of 
glucocorticoid and immunosuppressant treatment or who 
are intolerant to these drugs, B-cell depletion with rituximab 
appears to be a promising treatment [47,48]. Rapid clinical 
responses have been reported, with a dramatic decrease in 
serum IgG4 concentrations but not the concentrations of 
other IgG subclasses [49]. Reduction in serum IgG4 con-
centration correlated with clinical improvement within 
weeks. 
Bortezomib, a proteasome inhibitor that was initially 
used to treat multiple myeloma because of its cytotoxicity 
for plasma cells, has also been reported to be successful for 
treating other IgG4-related diseases [50]. No data are cur-
rently available regarding the efficacy of bortezomib for 
treating AIP. 
Large prospective studies are needed to evaluate the ef-
fectiveness of these biological agents and determine optimal 
treatment regimens. 
9  Prognosis 
Little is known about the natural history of AIP. Spontane-
ous remission occurs in a proportion of patients, who often 
have lower serum IgG4 levels, less obstructive jaundice and 
diabetes mellitus, and focal rather than diffuse enlargement 
of the pancreas on CT. Some patients relapse over time and 
many develop extrapancreatic manifestations. 
Kamisawa et al. [27] reported a relapse rate of 56% 
within 1 year and 92% within 3 years. The current evidence 
suggests that glucocorticoid maintenance therapy may be 
helpful in the prevention of disease relapse, even though the 
relapse rate remains high [51,52]. The potential risk factors 
for disease relapse in AIP include obstructive jaundice [51], 
extrapancreatic biliary ductal strictures [45,53], failure to 
achieve complete remission during maintenance therapy 
[54], and diffuse pancreatic swelling at baseline [55]. How-
ever, large prospective studies are needed to confirm these 
observations. 
Untreated AIP often progresses from lymphoplasmacytic 
inflammation to extensive fibrosis. The fibroinflammatory 
lesions may result in permanent organ dysfunction, and are 
associated with high morbidity and mortality rates. Cirrho-
sis and portal hypertension occur in some patients, devel-
oping over months or years after the initial onset of symp-
toms [45]. Patients with extensive fibrotic lesions may re-
spond less well to glucocorticoid and rituximab, although 
good treatment responses have been recorded in some cases 
[56]. AIP generally has a benign outcome if treated 
promptly. A study from the United States reported that both 
type I and type II AIP have 5-year survival rates similar to 
the age- and sex-matched general population [57]. 
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